Piramal Invests $30.6 Million in Coldstream Acquisition
Piramal Enterprises (PEL) announced on Jan. 16, 2015 that it had invested $30.6 million USD toward the acquisition of Coldstream Laboratories, a contract development and manufacturing organization focused on the development and manufacture of sterile injectables, in an all cash transaction. Of this investment, $5.6 million would be used to purchase Coldstream’s facility, adding to PEL’s multiple “Pharma Solutions” facilities in India, as well as locations in Canada and the UK, according to the website. The rest of the investment would go toward 100% of the company’s shares.
Coldstream is majority owned by the University of Kentucky Research Foundation, and operates from a facility in Lexington, Kentucky. According to the company website, it offers a variety of drug product manufacturing services including liquid and lyophilized parenterals, process development and optimization, terminal sterilization, aseptic and non-aseptic pilot scale manufacturing, preclinical to Phase III manufacturing, and niche commercial products. (http://www.coldstreamlabs.com/contract-manufacturing/)
Source:
Piramal
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
